Psychedelic clinical trial registry · updated 2026-08-25
86,898 people are needed
for these trials
right now.
Across 218 trials testing LSD, psilocybin, MDMA and ketamine for depression, PTSD, anxiety and addiction. Taking part is free, it is supervised, and for most people in most of the country it is the only lawful way in.
This is the registry of all of it, drawn from the public federal record. It does not tell anyone what to take, how much, or where to get it. For any medical question, talk to a doctor.
Find a trial recruiting now
218 open
Search by condition, or pick a state, to see what is open.
This filters a public registry. It does not decide whether you are eligible: that is done by each trial’s own investigators at a screening visit. Nothing you type here leaves your browser.
- 218
- Recruiting now
- 168
- Want patients, not healthy volunteers
- 43
- US states with a site
- 176
- Conditions being tested
By substance
Seven molecules, and how far each has come
The renaissance, as a shape
From 14 trials a year to 124
Psychedelic research effectively stopped for thirty years and restarted in the last ten. This is that restart in the registry’s own numbers, stacked by substance so you can see psilocybin arriving late and hard.
How far along any of this actually is
The pipeline, honestly
Every trial is counted once, at the furthest phase it has reached. Most sit in Phase 1 and Phase 2, and Phase 3 is thin by comparison. That matters when you read the news: a striking finding from an early-phase study is a result from one of the tall bars here, and an early-phase result is a reason to run a larger trial, not proof that something works.
- Phase 1Safety and dose
- A small group, often healthy volunteers. Establishes what dose can be given and what happens at it. Not designed to show whether the drug works.
- Phase 2Does it work, and what goes wrong
- A larger group who have the condition. Looks for a treatment effect and catalogs side effects. Most trials on this site are here or in Phase 1.
- Phase 3Confirmation against a comparison
- Hundreds to thousands of participants, measured against a placebo or an existing treatment. The last clinical stage before a company can file for approval.
- Phase 4After approval
- Monitoring once a medicine is on the market, for rarer effects and interactions that only appear at scale.
The near end of the pipeline
Phase 3 programs
Phase 3 is the last stage of clinical testing before a company can apply for approval. 96 of the 1,033 trials in this registry have reached it. What happens to those trials decides whether any of these medicines reach a pharmacy, where a doctor could prescribe them.
Recruiting now
218 trials are accepting participants
Status is as recorded on ClinicalTrials.gov API v2 at the 2026-08-25 data build. A trial can close to entry between builds, so the registry record is always the authority.
By indication
What these are being tested for
- Major Depressive Disorder173
- Depression120
- Post Traumatic Stress Disorder86
- Treatment Resistant Depression84
- Suicidal Ideation36
- Anxiety31
- Alcohol Use Disorder30
- Obsessive-Compulsive Disorder28
- Depressive Disorder, Treatment-Resistant25
- Bipolar Depression24
- Posttraumatic Stress Disorder21
- Depressive Disorder21
- Bipolar Disorder18
- Opioid Use18
- Postoperative Pain17
By place
Where trials are running
Results scheduled for release
When these trials report
A trial answers its question on its primary completion date, the day the last participant is measured for the trial’s main outcome. 285 of those dates are still in the future. The Phase 3 trials among them are the ones that decide whether any of this becomes a prescription.
- Ketamine for Methamphetamine Use Disorder2026-08
- "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"2026-08
- Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN2026-08
- Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness2026-08
- A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)2026-08
- Ketamine Augmentation of ECT in Treatment-Resistant Depression2026-08
Nothing open for you today?
That changes constantly
Trials open, fill and close on their own schedule, and the registry turns over far faster than anyone thinks to check a website. If nothing matches you today, that is a statement about today.
We will email you when something does. Your address and the topic you asked about is all we keep.
How this works
A registry, not an advocate
Every row is a public record
All 1,033 trials come from ClinicalTrials.gov API v2. Nothing here is written by a model, and every page carries the NCT number so you can check it against the source.
No advice, no sourcing
This site does not tell anyone what to take, how much, or where to get it. It publishes what is in the registry and points at the people running it.
The search runs on your device
The trial search filters a file your browser has already downloaded, so the condition, state and substance you pick are never sent here. The site counts page views and carries no advertising trackers at all, and the analytics it does run is barred from joining what you read to any ad profile. The privacy policy sets out exactly what leaves your browser.